miRagen Therapeutics (MGEN) Tops Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MGEN Hot Sheet
Join SI Premium – FREE
miRagen Therapeutics (NASDAQ: MGEN) reported Q3 EPS of ($0.27), $0.12 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million, versus $900 thousand reported last year.
For earnings history and earnings-related data on miRagen Therapeutics (MGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- Datadog stock tumbles 19% despite earnings beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
